[IBB] iShares Nasdaq Biotechnology Index Fund

Overview

Type of security: Fund

Tags: Biotech, Country, Equity, ETF, Health, Health care, Healthcare, Index Based, Not Inversed, Sector, Stocks, U.S., Unleveraged

The data is delayed by 15 minutes.

 

Price: 272.32 Change: 5.62 (2.11%)
Ext. hours: 274.4 Change: 2.08 (0.76%)

chart IBB

Refresh chart

Strongest Trends Summary For IBB

IBB is in the medium-term down -10% in 7 months. In the long-term up 62% above S&P in 20 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

See how to gain 20% in 14 sec with TrendsInvesting

Technical Data
High 52 week122.16 Low 52 week96.21 Last close96.21 Last change-2.14%
RSI23.11 Average true range3.24 Beta0.99 Volume1.25 M
Simple moving average 20 days-7.65% Simple moving average 50 days-9.54% Simple moving average 200 days-13.16%
Performance Data
Performance Week-8.79% Performance Month-8.42% Performance Quart-18.21% Performance Half-15.41%
Performance Year-9.31% Performance Year-to-date-9.76% Volatility daily1.62% Volatility weekly3.62%
Volatility monthly7.43% Volatility yearly25.72% Relative Volume180.65% Average Volume2.11 M
New High New Low
Funds Characteristics
30-day SEC yield Average market capitalization Average weighted market capitalization Forward P/E
Gross expense ratio Index dividend yield Median market cap Number of holdings0
Price to Book Value 9.9 Price to Earnings40.91 Total expense ratio0.48% Total net assets4.92 B
Weighted market capitalization

Info

Characteristics:
NAME VALUE
Total Expense Ratio0,48
Number Of Holdingsn/a
Total Net Assets4 915 409 116,00
P/E Ratio40,91
P/Bv Ratio9,9
Top Holdings:
NAME VALUE
Amgen Inc8,91
Biogen Idec Inc8,04
Celgene Corp7,78
Gilead Sciences Inc7,67
Alexion Pharmaceuticals Inc6,78
Regeneron Pharmaceuticals Inc4,04
Mylan Inc3,93
Vertex Pharmaceuticals Inc3,92
Illumina Inc3,88
Biomarin Pharmaceutical Inc2,36
Sector Breakdown:
NAME VALUE
Biotechnology78,14
Pharmaceuticals21,85
S-t Securities0,04

News

2019-03-21 11:16:40 | Biotech Funds Could Generate Profitable Short Sales

2019-03-21 06:52:00 | Novocure Chief Science Officer Eilon Kirson to retire after 7 years in the role

2019-03-20 07:07:11 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?

2019-03-18 15:05:00 | Aerpio Pharmaceuticals stock plummets after failed trial of diabetic retinopathy treatment

2019-03-18 13:12:00 | Dare Bioscience stock rockets to pace all gainers after positive findings from VVA treatment study

2019-03-18 07:29:00 | PhaseBio's stock more than doubles after positive phase 1 trial results of ticagrelor reversal agent

2019-03-14 15:51:00 | Gilead Stock Could Surge to $84, Says Analyst

2019-03-13 10:35:00 | Akari Therapeutics' stock rockets on massive volume after 'successful' pre-IND FDA meeting

2019-03-11 12:27:09 | Is iShares Nasdaq Biotechnology Index Fund a Buy?

2019-03-10 14:32:48 | The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings, IPOs

2019-03-05 15:32:00 | Biotech stocks turn lower after reports of FDA commissioner resigning

2019-03-05 08:00:00 | CNBC ETF Edge: Biotech Getting Sick?

2019-03-04 13:44:05 | How you should trade the biotech ETFs

2019-03-04 08:39:00 | Nightstar Therapeutics' stock rockets on Biogen buyout deal valued at $877 million

2019-03-01 06:51:00 | Immunogen's stock loses nearly half its value after trial of cancer treatment fails to meet primary endpoint

2019-02-27 15:00:32 | 7 of the Best Biotech ETFs

2019-02-20 09:32:02 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?

2019-02-14 13:00:06 | Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings

2019-02-12 15:21:00 | Anchiano Therapeutics' stock set to close well below its IPO price

2019-02-12 09:29:00 | Anchiano Therapeutics IPO prices below assumed price

2019-02-07 10:49:00 | Alector's stock opens below IPO price, then swings above it

2019-01-29 08:56:10 | Biogen Stock Running in Place Despite Strong Quarter

2019-01-28 15:52:46 | What Are Analysts Recommending for AbbVie after Q4 2018 Results?

2019-01-28 08:52:00 | Amgen downgraded to in-line from outperform by Evercore ISI

2019-01-25 13:36:00 | MacroGenics stock gains 4% after FDA lifts partial clinical hold

2019-01-25 10:02:22 | Intuitive Surgical Stock Dips Are Buying Opportunities

2019-01-25 08:32:00 | NuCana's stock soars after withdrawing ADS offering, which triggered a big selloff

2019-01-24 13:00:06 | What's Behind the Biotech ETF Rally to Start 2019?

2019-01-23 07:51:00 | Rigel Pharmaceuticals stock up 9% after announcing licensing agreement with Grifols

2019-01-22 11:06:00 | Editas stock down 21% after announcing CEO departure

2019-01-22 09:17:00 | Ultragenyx stock up 2.9% after safety and efficacy trial reaffirms Phase 2 data

2019-01-17 09:10:00 | Lipocine's stock rockets on premarket leading volume after upbeat liver fat study results

2019-01-17 07:13:02 | Trade of the Day: The Biotechnology Stocks ETF Is Running Out of Steam

2019-01-17 07:00:00 | Trending: Investors Turn to Dividend Aristocrats Amid Market Volatility

2019-01-16 12:26:40 | Aptinyx Stock Plunged 70% after Clinical Trial Failure

2019-01-16 09:19:00 | Aptinyx stock falls 67% after phase 2 trial fails to meet primary endpoint

2019-01-11 10:59:27 | Why Sarepta Therapeutics Stock Is Starting to Shine Again

2019-01-11 08:30:00 | Bear market in value stocks is ending, Wells Fargo predicts a 2019 comeback

2019-01-08 08:00:00 | Two ways to play the biotech boom

2019-01-08 07:24:00 | Biotech's breaking out, and here's why some market experts think an even bigger rally is ahead

2019-01-07 15:02:25 | Three Healthcare Stocks Rallying Over 10% Today

2019-01-07 13:27:00 | Sage Therapeutics's stock shoots higher after postpartum depression treatment's positive trial results

2019-01-07 13:27:00 | Sage Therapeutics's stock shoots higher after postpartum depression treatment's positive trial results

2019-01-07 12:53:00 | ETF Edge, January 7, 2019

2019-01-07 12:26:00 | ETF Edge: Biotech breakout

2019-01-07 08:23:00 | Axsome's stock nearly triples on heavy volume after positive trial of depression treatment

2019-01-04 16:35:00 | Insmed stock shoots up 18% after company says it expects drug Arikayce to bring in $9.8 million in fourth quarter

2019-01-04 10:01:03 | Bristol-Myers to Acquire Celgene: Healthcare ETFs in Focus

2019-01-04 07:13:00 | Mersana to discontinue development of one cancer treatment to focus on another

2018-12-31 09:00:22 | Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates